Back to Search Start Over

Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells

Authors :
Nassera Aouali
Lahcen Eddabra
Hassan El Btaouri
Claudie Madoulet
Hamid Morjani
Charles Dumontet
Sophie Malagarie-Cazenave
Equipe 14
Oncogénèse et progression tumorale
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL )
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL )
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre de Recherche en Cancérologie de Lyon ( CRCL )
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )
Laboratoire d'Onco-Pharmacologie ( LOP )
Université de Reims Champagne-Ardenne ( URCA ) -JE2428
Université de Reims Champagne-Ardenne ( URCA )
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Laboratoire d'Onco-Pharmacologie (LOP)
Université de Reims Champagne-Ardenne (URCA)-JE2428
Université de Reims Champagne-Ardenne (URCA)
Source :
Oncology Reports, Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. 〈10.3892/or.2011.1180〉, Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. ⟨10.3892/or.2011.1180⟩
Publication Year :
2011
Publisher :
HAL CCSD, 2011.

Abstract

International audience; The selection pressure for resistance to chemotherapy is accompanied by the enhanced expression of ABC proteins and increased cellular glycosphingolipid content. Thus, a possible connection between glycosphingolipid metabolism and ABC proteins in drug resistance has been suggested. In the present study, we established two human multidrug-resistant (MDR) cell lines derived from MESSA sarcoma cells by culturing with increasing concentrations of doxorubicin (DX5 cells) or doxorubicin together with cyclosporin A (GARF cells). Both resistant cell lines overexpressed the MDR1 gene and the wild-type P-glycoprotein at the same level. The cyclosporin derivative PSC833, a potent inhibitor of P-glycoprotein, sensitized DX5 but not GARF cells to the cytotoxic effects of daunorubicin. Moreover, PSC833 increased the nuclear accumulation of daunorubicin and the cellular accumulation of [3H]vinblastine in the DX5 but not in the GARF cells. The cellular incorporation of [3H]-cyclosporin A was lower in DX5 cells compared to MESSA and GARF cells, which incorporated the same level of [3H]-cyclosporin A. Sphingolipid analysis showed that the lactosylceramide level was 2.5- and 5-fold higher in DX5 and GARF cells, respectively, than in MESSA cells. Whereas the pharmacological inhibition of lactosylceramide synthesis was able to reverse only partially the resistance of GARF cells to daunorubicin without significant increase in nuclear accumulation of the drug, the same treatment before the co-treatment with PSC833 and daunorubicin increased the cytotoxic effect of daunorubicin and its nuclear accumulation. These data suggest a possible relationship between lactosylceramide levels and the resistance of P-glycoprotein to modulation by MDR modulators.

Subjects

Subjects :
Cancer Research
MESH : RNA, Messenger
MESH: Flow Cytometry
MESH : Blotting, Western
MESH : Lactosylceramides
MESH : P-Glycoprotein
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
0302 clinical medicine
MESH : Tumor Cells, Cultured
MESH: Reverse Transcriptase Polymerase Chain Reaction
Cyclosporin a
Tumor Cells, Cultured
polycyclic compounds
MESH : Cell Proliferation
Cytotoxic T cell
MESH: Cyclosporins
MESH: Antigens, CD
P-glycoprotein
0303 health sciences
music.instrument
Antibiotics, Antineoplastic
biology
Reverse Transcriptase Polymerase Chain Reaction
MESH : Reverse Transcriptase Polymerase Chain Reaction
Sarcoma
General Medicine
Flow Cytometry
MESH: Drug Resistance, Neoplasm
Drug Resistance, Multiple
MESH : Antibiotics, Antineoplastic
3. Good health
MESH : Drug Resistance, Neoplasm
Oncology
Biochemistry
030220 oncology & carcinogenesis
MESH: Daunorubicin
medicine.drug
MESH: P-Glycoprotein
Daunorubicin
MESH : Flow Cytometry
Blotting, Western
Lactosylceramides
[SDV.CAN]Life Sciences [q-bio]/Cancer
Cyclosporins
MESH : Sarcoma
MESH: Drug Resistance, Multiple
MESH: Doxorubicin
03 medical and health sciences
Lactosylceramide
Antigens, CD
MESH: Cell Proliferation
medicine
MESH : Antigens, CD
MESH: Blotting, Western
Humans
MESH : Doxorubicin
Doxorubicin
MESH: Tumor Cells, Cultured
ATP Binding Cassette Transporter, Subfamily B, Member 1
RNA, Messenger
MESH : Cyclosporins
MESH: Antibiotics, Antineoplastic
MESH: Lactosylceramides
music
MESH: RNA, Messenger
030304 developmental biology
Cell Proliferation
MESH: Humans
MESH : Humans
Molecular biology
Multiple drug resistance
Cell culture
Drug Resistance, Neoplasm
MESH: Sarcoma
biology.protein
MESH : Daunorubicin
MESH : Drug Resistance, Multiple

Details

Language :
English
ISSN :
1021335X
Database :
OpenAIRE
Journal :
Oncology Reports, Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. 〈10.3892/or.2011.1180〉, Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. ⟨10.3892/or.2011.1180⟩
Accession number :
edsair.doi.dedup.....7b3533101879df2b23e9d6bdd90421dc